We identified a potential CES3 enhancer peak located ~5 kb upstream of the CES3 transcriptional start site (TSS), displaying consistently lower accessibility in tumor cells of all BAP1 mutants as compared with other tumors (Fig. 7d) and PT cells from NATs (Supplementary Fig. 6d). The gene discussed is CES3; the disease is neoplasm.